Trial Profile
A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2022
Price :
$35
*
At a glance
- Drugs Prexasertib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 26 Jul 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Jun 2021.
- 10 Dec 2019 Status changed from recruiting to active, no longer recruiting.